Abstract
The gonadal steroid 17β-estradiol (E2) has shown powerful cytoprotective effect on cells. In addition to classical genomic mechanisms of action, E2 also exerts non-classical effects on intracellular signal transduction. Extensive studies during the past two decades have provided evidence that the E2-induced non-classical signaling on second messenger molecules plays a critical role in the neuroprotective effect of E2. These observations provide a unique basis for developing non-classical estrogen-like signaling activators that may have potential for clinical use in neuroprotection. In spite of the extensive research over the past decade reviewed here, we are just starting to appreciate the importance and potential of these compounds. Hence, we first describe the molecular characteristics and effects of these activators. Second, we survey recent data as to possible mechanisms underlying the ameliorative actions of selective non-classical estrogen-like signaling activation. In addition, the pitfalls and future aspects of “non-classical”-line activators and its clinical relevance will also be discussed.
Keywords: Estradiol, non-classical estrogen-like signaling activators, ANGELS, estren, compound A, compound B, neuroprotection.
CNS & Neurological Disorders - Drug Targets
Title:Neuroprotective Effects of Non-Classical Estrogen-Like Signaling Activators: from Mechanism to Potential Implications
Volume: 12 Issue: 8
Author(s): Andrea Kwakowsky, Zsombor Koszegi, Rachel Y. Cheong and Istvan M. Abraham
Affiliation:
Keywords: Estradiol, non-classical estrogen-like signaling activators, ANGELS, estren, compound A, compound B, neuroprotection.
Abstract: The gonadal steroid 17β-estradiol (E2) has shown powerful cytoprotective effect on cells. In addition to classical genomic mechanisms of action, E2 also exerts non-classical effects on intracellular signal transduction. Extensive studies during the past two decades have provided evidence that the E2-induced non-classical signaling on second messenger molecules plays a critical role in the neuroprotective effect of E2. These observations provide a unique basis for developing non-classical estrogen-like signaling activators that may have potential for clinical use in neuroprotection. In spite of the extensive research over the past decade reviewed here, we are just starting to appreciate the importance and potential of these compounds. Hence, we first describe the molecular characteristics and effects of these activators. Second, we survey recent data as to possible mechanisms underlying the ameliorative actions of selective non-classical estrogen-like signaling activation. In addition, the pitfalls and future aspects of “non-classical”-line activators and its clinical relevance will also be discussed.
Export Options
About this article
Cite this article as:
Kwakowsky Andrea, Koszegi Zsombor, Cheong Y. Rachel and Abraham M. Istvan, Neuroprotective Effects of Non-Classical Estrogen-Like Signaling Activators: from Mechanism to Potential Implications, CNS & Neurological Disorders - Drug Targets 2013; 12 (8) . https://dx.doi.org/10.2174/187152731131200123
DOI https://dx.doi.org/10.2174/187152731131200123 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab
Current Cancer Therapy Reviews Studies on Cancer Cell Cytotoxicity, Antimicrobial Activity of Sol-Gel Synthesized Willemite for Biomedical Applications
Current Nanoscience Management of Gestational Trophoblastic Diseases-An Update
Reviews on Recent Clinical Trials Anticancer Evaluation of 3,4,5,4'-trans-tetramethoxystilbene (DMU-212) and Its Analogs Against an Extensive Panel of Human Tumor Cell Lines
Letters in Drug Design & Discovery Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets Cerebral Artery Signal Transduction Mechanisms: Developmental Changes in Dynamics and Ca<sup>2+</sup> Sensitivity
Current Vascular Pharmacology Phytocompounds from the Medicinal and Dietary Plants: Multi-target Agents for Cervical Cancer Prevention and Therapy
Current Medicinal Chemistry Physical Characterisation and Stability Study of Formulated <i>Chromolaena odorata</i> Gel
Current Drug Delivery Botulinum Toxin: Pharmacology and Clinical Developments: A Literature Review
Medicinal Chemistry Biological Activity of Carotenoids: Its Implications in Cancer Risk and Prevention
Current Pharmaceutical Biotechnology Targeted Inhibition of AKT in Pancreatic Cancer
Current Cancer Therapy Reviews Anticancer Activity of Selenium Nanoparticles <i>In Vitro</i> Studies
Anti-Cancer Agents in Medicinal Chemistry Schiff Bases and their Metal Complexes as Potential Anticancer Candidates: A Review of Recent Works
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Anticancer Activity of 2-Aryl-6-diethylaminoquinazolinone Derivatives
Letters in Drug Design & Discovery Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma
Current Medicinal Chemistry Genitourinary Tract Tumors in Children: An Update
Current Pediatric Reviews Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Phytochemicals as Adjunctive with Conventional Anticancer Therapies
Current Pharmaceutical Design Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae
Current Molecular Medicine Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry